Trial Profile
A proof-of-concept, safety and tolerability study of SPI-026 in patients with pulmonary arterial hypertension
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2015
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Proof of concept
- 30 Mar 2015 New trial record
- 18 Mar 2015 According to a Selten Pharma media release, SPI-026 has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) for the treatment of pulmonary arterial hypertension.